Jubilant Biosys (BVI) Ltd

Balance Sheet

As at 31 March	Notes No	2016	2016	2015	2015
		USD	INR (' In	USD	INR (' In
			Thousands)		Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds]			
Share capital	1	13,97,501	69,846	13,97,501	69,846
Reserves and surplus	2	- 31,293	20,665	- 27,134	15,802
		13,66,208	90,511	13,70,367	85,648
Current liabilities					
Trade payables	3	8,287	549	2,826	177
		8,287	549	2,826	177
	Total	13,74,495	91,060	13,73,193	85,825
II. ASSETS					
Non-current investments	4	13,71,501	90,862	13,71,501	85,719
		13,71,501	90,862	13,71,501	85,719
Current assets					
Cash and bank balances	5	1,371	91	1,371	86
Short-term loans and advances	6	1,623	108	321	20
	,	2,994	198	1,692	106
	Total	13,74,495	91,060	13,73,193	85,825

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida Date :23 May 2016

JUBILANT BIOSYS (BVI) LTD Statement of Profit and Loss

For the year ended 31st March,	Notes No	2016	2016	2015	2015
Particulars		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES			,		,
Other expenses	7 -	4,160	- 271	4,257	261
Total expenses	[-	4,160	- 271	4,257	261
(Loss) for the Year	-	4,160	- 271	- 4,257	- 261

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida Date :23 May 2016 Jubilant Biosys (BVI) Ltd

Cash flow Statement for the Year Ended 31 March	2016	2016	2015	2015
Particulars Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Cash flows from operating activities				
Net loss before minority interest	(4,160)	(271)	(4,257)	(261)
Operating profit before working capital changes	(4,160)	(271)	(4,257)	(261)
Adjustments for :				
(Increase) in trade and other receivables	(1,302)	(85)	(92)	(6)
Increase in trade and other payables	5,462	356	1,546	
-	4,160	271	1,454	89
A. Net cash inflow/(outflow) in course of operating activities	-	-	(2,803)	(172)
B. Foreign currency translation difference arising on consolidation		5		8
Net Increase in cash and cash equivalents (A+B)		5	(2,803)	(164)
Add: cash and cash equivalents at the beginning of year	1,371	86	4,174	250
Cash & cash equivalents at the close of the year	1,371	91	1,371	86

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)
Place: Noida
Date: 23 May 2016

¹⁾ cash Flow Statement has been prepared under the direct method as set out in Accounting Standard 3(AS-)-" Cash Flow Statements"

Jubilant Biosys (BVI) Ltd

Notes to the Financial Statements

As at 31 March	2016	2016	2015	2015
Particulars	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
1. SHARE CAPITAL				
Issued and Subscribed				
1,397,501 equity shares of USD 1 each	13,97,501	69,846	13,97,501	69,846
Preference share capital	-	-	-	-
(Previous Year 1,397,501 equity shares of USD 1 each)	13,97,501	69,846	13,97,501	69,846
	-	-		
Paid up				
1,397,501 equity shares of USD 1 each	13,97,501	69,846	13,97,501	69,846
(Previous Year 1,397,501 equity shares of USD 1 each)	-	-		
Add: equity shares forfeited (paid up)	-	-	-	-
	13,97,501	69,846	13,97,501	69,846

- 1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.
- 1.2)In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.
- 3) The details of shareholders holding more than 5% shares as at 31 March, 2016 and 31March, 2015 is set out below:

As at 31 March	2016	2016	2015	2015
Name of the shareholder	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company	13,97,501	1	13,97,501	1

4) The reconciliation of the number of shares outstanding as at 31 March,2016 and 31 March,2015 is set out below:

As at 31 March	2016	2016	2015	2015
Name of the shareholder	No.	'INR (' In	No.	'INR (' In
		Thousands)		Thousands)
Numbers of shares at the beginning	13,97,501	69,846	13,97,501	69,846
Add: Shares issued during the year	-	-		
Numbers of shares at the end	13,97,501	69,846	13,97,501	69,846

5)Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31 March	2016	2016	2015	2015
Particulars	No.	'INR (' In	No.	'INR (' In
		Thousands)		Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company	13,97,501	69,846	13,97,501	69,846
1,397,501 equity shares of USD 1 each				

Jubilant Biosys (BVI) Ltd Notes to the Financial Statements

As at 31 March	2016	2016	2015	2015
Particulars	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
2. RESERVES AND SURPLUS	i d			
Foreign Currency Translation Reserve	İ			
Foreign Currency Transalation Reserve Opening	-	17,229	_	13,674
Foreign Currency Transalation Reserve During the Year	-	5,134	-	3,555
	-	22,363		17,229
Surplus as per P&L Account				
As per last Balance Sheet	- 27,134	- 1,427	- 22,877	- 1,166
Add: Net Profit after tax transferred from Statement of Profit and Loss	- 4,160	- 271	- 4,257	- 261
ridar recerronicates can diameter earnoth ocacement of front and 2000	- 31,293	- 1,698	- 27,134	- 1,427
Less: Appropriations	32,235	2,030	27,254	2,72.7
	- 31,293	20,665	- 27,134	15,801
3. TRADE PAYABLES	5.5,255			
Trade payables-others	8,287	549	2,826	177
Trade payables-others	8,287	549 549	2,826 2,826	177
	0,207	343	2,020	
4. NON CURRENT INVESTMENTS				
nvestment in Subisidiary/Fellow Subsidiaries Companies	13,71,501	90,862	13,71,501	85,719
lubilant Biosys (Singapore) Pte Ltd		, l	, ,	,
1371501 shares of USD 1 each	13,71,501	85,719	13,71,501	85,719
5. CASH AND BANK BALANCES				
Balances with banks:				
- On current accounts	1,371	91	1,371	86
	1,371	91	1,371	86
5. SHORT TERM LOANS AND ADVANCES				
	1.022	100	224	20
- Prepaid Expenses	1,623	108 108	321 321	20
	1,623	108	321	20
. OTHER EXPENSE]		:	
egal, professional and consultancy charges	4,150	270	4,237	260
Bank Charges	10	1	20	1
	4,160	271	4,257	261